Persistent humoral immune response in youth throughout the … – Nature.com

Szpfalusi, Z. et al. Lessons from low seroprevalence of SARSCoV2 antibodies in schoolchildren: a crosssectional study. Pediatr. Allergy Immunol. 32, 762770 (2021).

Article PubMed PubMed Central Google Scholar

Oeser, C. et al. Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the delta wave and vaccination. J. Infect. 84, 418467 (2022).

Article CAS PubMed Google Scholar

Ladhani, S. N. et al. SARS-CoV-2 infection and transmission in primary schools in England in JuneDecember, 2020 (sKIDs): an active, prospective surveillance study. Lancet Child Adolesc. Health 5, 417427 (2021).

Article CAS PubMed PubMed Central Google Scholar

Ott, R. et al. SARS-CoV-2 seroprevalence in preschool and school-age children population screening findings from January 2020 to June 2022. Dtsch. Arztebl. Int. 119, 765770 (2022).

PubMed PubMed Central Google Scholar

Sorg, A.-L. et al. Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. Nat. Commun. 13, 3128 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Clarke, K. E. N. et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies United States, September 2021February 2022. MMWR Morb. Mortal. Wkly Rep. 71, 606608 (2022).

Article CAS PubMed PubMed Central Google Scholar

Zaballa, M.-E. et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study. Lancet Reg. Health Eur. 24, 100547 (2023).

Article PubMed Google Scholar

Richard, A. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. Scand. J. Public Health 50, 124135 (2022).

Article PubMed Google Scholar

Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance 26, 2100830 (2021).

Article CAS PubMed PubMed Central Google Scholar

Buonsenso, D. et al. Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies. Front. Immunol. 13, 1024924 (2023).

Article PubMed PubMed Central Google Scholar

Lin, D.-Y. et al. Effects of vaccination and previous infection on Omicron infections in children. N. Engl. J. Med. 387, 11411143 (2022).

Article PubMed Google Scholar

Frenck, R. W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 385, 239250 (2021).

Article CAS PubMed Google Scholar

Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 Years of Age. N. Engl. J. Med. 386, 3546 (2022).

Article CAS PubMed Google Scholar

Price, A. M. et al. BNT162b2 protection against the Omicron variant in children and adolescents. N. Engl. J. Med. 386, 18991909 (2022).

Article CAS PubMed Google Scholar

News: Canton of Zurich. Canton of Zurich https://www.zh.ch/de/news-uebersicht.html?page=1&orderBy=new (2023).

Lyngse, F. P. et al. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. Nat. Commun. 13, 5573 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N. & Bull, R. A. Evolution of the SARSCoV2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 32, e2381 (2022).

Article CAS PubMed PubMed Central Google Scholar

del Rio, C., Omer, S. B. & Malani, P. N. Winter of Omicronthe evolving COVID-19 pandemic. JAMA 327, 319 (2022).

Article PubMed Google Scholar

Leone, V. et al. Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study. PLoS ONE 17, e0272874 (2022).

Article CAS PubMed PubMed Central Google Scholar

Bloise, S. et al. Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults. Eur. J. Pediatr. 180, 33353342 (2021).

Article CAS PubMed PubMed Central Google Scholar

Mndez-Echevarra, A. et al. Long-term persistence of anti-SARS-CoV-2 antibodies in a pediatric population. Pathogens 10, 700 (2021).

Article PubMed PubMed Central Google Scholar

Bonfante, F. et al. Mild SARS-CoV-2 infections and neutralizing antibody titers. Pediatrics 148, e2021052173 (2021).

Article PubMed Google Scholar

Renk, H. et al. Robust and durable serological response following pediatric SARS-CoV-2 infection. Nat. Commun. 13, 128 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Dunay, G. A. et al. Long-term antibody response to SARS-CoV-2 in children. J. Clin. Immunol. 43, 4656 (2023).

Article CAS PubMed Google Scholar

Di Chiara, C. et al. Long-term immune response to SARS-CoV-2 infection among children and adults after mild infection. JAMA Netw. Open 5, e2221616 (2022).

Article PubMed PubMed Central Google Scholar

Dowell, A. C. et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat. Immunol. 23, 4049 (2022).

Article CAS PubMed Google Scholar

Cohen, K. W. et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med 2, 100354 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wei, J. et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat. Commun. 12, 6250 (2021).

Article ADS CAS PubMed PubMed Central Google Scholar

Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).

Article ADS CAS PubMed PubMed Central Google Scholar

Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (1979) 371, eabf4063 (2021).

CAS Google Scholar

Menges, D. et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nat. Commun. 13, 4855 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Lau, E. H. et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine 41, 101174 (2021).

Article PubMed PubMed Central Google Scholar

Chou, J., Thomas, P. G. & Randolph, A. G. Immunology of SARS-CoV-2 infection in children. Nat. Immunol. 23, 177185 (2022).

Article CAS PubMed PubMed Central Google Scholar

Yoshida, M. et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature 602, 321327 (2022).

Article ADS CAS PubMed Google Scholar

Frei, A. et al. Development of hybrid immunity during a period of high incidence of Omicron infections. Int. J. Epidemiol. 00, dyad098 (2023) .

Suryawanshi, R. & Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining? Nat. Rev. Immunol. 22, 591592 (2022).

Article CAS PubMed PubMed Central Google Scholar

Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N. Engl. J. Med. 386, 12071220 (2022).

Article CAS PubMed Google Scholar

Goldberg, Y. et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N. Engl. J. Med. 386, 22012212 (2022).

Article CAS PubMed Google Scholar

Spinardi, J. R. & Srivastava, A. Hybrid immunity to SARS-CoV-2 from infection and vaccinationevidence synthesis and implications for new COVID-19 vaccines. Biomedicines 11, 370 (2023).

Article CAS PubMed PubMed Central Google Scholar

Althaus, T. et al. The impact of severe acute respiratory syndrome coronavirus 2 vaccination and infection on neutralizing antibodies: a nation-wide cross-sectional analysis. J. Infect. Dis. 227, 12551265 (2023).

Article PubMed Google Scholar

Fenwick, C. et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci. Transl. Med 13, eabi8452 (2021).

Article CAS PubMed PubMed Central Google Scholar

Dowell, A. C. et al. Immunological imprinting of humoral immunity to SARS-CoV-2 in children. Nat. Commun. 14, 3845 (2023).

Article ADS CAS PubMed PubMed Central Google Scholar

Allen, N. et al. Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals. J. Infect. 83, e9e10 (2021).

Article CAS PubMed PubMed Central Google Scholar

Dhakal, S. et al. Reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients. Open Forum Infect. Dis. 10, ofac677 (2023).

Article PubMed Google Scholar

Follmann, D. et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann. Intern. Med. 175, 12581265 (2022).

Article PubMed Google Scholar

Tenforde, M. W. et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adultsUnited States, MarchJuly 2021. MMWR Morb. Mortal. Wkly Rep. 70, 11561162 (2021).

Article CAS PubMed PubMed Central Google Scholar

Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N. Engl. J. Med. 386, 340350 (2022).

Article CAS PubMed Google Scholar

Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395404 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch. Dis. Child 106, 429439 (2021).

Article Google Scholar

National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/special-considerations-in-children/ (2023).

Marks, K. J. et al. Hospitalizations of children and adolescents with laboratory-confirmed COVID-19COVID-NET, 14 States, July 2021January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 271278 (2022).

Article CAS PubMed PubMed Central Google Scholar

Coronavirus (COVID-19) latest insights: Hospitals. Office for National Statistics https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals#hospital-admissions-by-age (2023).

Read more from the original source:

Persistent humoral immune response in youth throughout the ... - Nature.com

Related Posts
Tags: